{
    "2018-07-12": [
        [
            {
                "time": "",
                "original_text": "[买入评级]恒瑞医药(600276)：SHR-1701和SHR1209获批临床 新药研发管线深化",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "SHR-1701",
                        "SHR1209",
                        "获批临床",
                        "新药研发"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "485亿资金争夺20股：主力资金重点出击17股(名单)",
                "features": {
                    "keywords": [
                        "资金争夺",
                        "主力资金",
                        "股票名单"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "[推荐评级]医药国家药品监督管理局发布《接受药品境外临床试验数据的技术指导原则》点评：接受境外实验数据细则公布 新药上市“时差”有望显著缩短",
                "features": {
                    "keywords": [
                        "国家药品监督管理局",
                        "境外临床试验",
                        "技术指导原则",
                        "新药上市",
                        "时差缩短"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "恒瑞医药：两款注射剂获批 将开展I期临床试验",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "注射剂",
                        "获批",
                        "I期临床试验"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "天士力：生物药平台价值初显 引领天士力价值重估",
                "features": {
                    "keywords": [
                        "天士力",
                        "生物药平台",
                        "价值重估"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}